Uniqure NV

NASDAQ QURE

Download Data

Uniqure NV Gross Profit for the quarter ending March 31, 2024: USD -3.37 M

Uniqure NV Gross Profit is USD -3.37 M for the quarter ending March 31, 2024, a -216.61% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Uniqure NV Gross Profit for the quarter ending March 31, 2023 was USD 2.89 M, a 61.27% change year over year.
  • Uniqure NV Gross Profit for the quarter ending March 31, 2022 was USD 1.79 M, a 294.71% change year over year.
  • Uniqure NV Gross Profit for the quarter ending March 31, 2021 was USD 454.00 K, a 336.54% change year over year.
  • Uniqure NV Gross Profit for the quarter ending March 31, 2020 was USD 104.00 K, a -90.85% change year over year.
NASDAQ: QURE

Uniqure NV

CEO Mr. Matthew Craig Kapusta
IPO Date June 20, 2007
Location Netherlands
Headquarters Paasheuvelweg 25a, Amsterdam, Netherlands, 1105 BP
Employees 480
Sector Healthcare
Industry Biotechnology
Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

STRO

Sutro Biopharma

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

REPL

Replimune Group Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email